Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:completedIn |
2022
|
| gptkbp:conditionStudied |
gptkb:Pompe_disease
|
| gptkbp:enrollment |
64
|
| https://www.w3.org/2000/01/rdf-schema#label |
MAZE-001 Phase 1
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:period |
Phase 1
|
| gptkbp:purpose |
safety
tolerability |
| gptkbp:sponsor |
gptkb:Maze_Therapeutics
|
| gptkbp:startDate |
2021
|
| gptkbp:status |
completed
|
| gptkbp:studyDrug |
MZE001
|
| gptkbp:studyType |
interventional
|
| gptkbp:bfsParent |
gptkb:Maze_Therapeutics
|
| gptkbp:bfsLayer |
7
|